Citryll

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the companys lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm

Immunology,therapeutics development,neutrophil extracellular traps,inflammatory diseases,antibody development,rheumatoid arthritis,and hidradenitis suppurativa

Citryll operates in the Biotechnology research industry.

Citryll's revenue is 1m - 10m

Citryll has 11 - 50 employees.